State–Federal Legal Conflicts

Baystate Health has paused prescribing puberty blockers and cross‑sex hormones for patients under 18, citing an “evolving regulatory landscape” that could jeopardize hundreds of millions in Medicare and Medicaid reimbursement, and says it will focus on gender‑affirming mental‑health counseling and transfer affected minors to a regional nonprofit. The decision comes amid Trump administration actions—a proposed HHS rule tying Medicare/Medicaid participation to bans on certain procedures for minors, an HHS review, DOJ subpoenas and public endorsements of professional statements delaying youth surgery—and rising malpractice concerns that have already led large systems like Kaiser and NYU Langone to curtail youth gender care.